A recent study in The Lancet Psychiatry forecasts that half of the global population will experience a mental health disorder in their lifetime. Yet current treatments fall short for up to one third of patients, with treatment resistant major depressive disorder, schizophrenia, and generalized anxiety disorder, among others. To address these failures, there are two paths ahead for innovation: design better drugs for established targets or test entirely new biological mechanisms. Join our panel of experts, each with a unique approach to novel drug development for brain disorders, as they explore the current landscape of innovation in neuropsychiatric drugs and debate where to best direct new efforts. This discussion holds increasing significance within the context of a global mental health treatment market that is expected to exceed $500 billion by 2028.